Navigation Links
Managed Compliance Services Program (MCSP) Introduced for Small Healthcare Practitioners
Date:8/19/2008

lly the Security Rule. This can become a national problem because when you add them all up, they add up to be a significant sector of the healthcare industry, making EPHI at risk in a huge and incomprehensible sense," said Gerry Dumatol founder and president of DumaTek(TM), a California Corporation that specializes in HIPAA in the small business sector in healthcare.

ComplianceALL(TM) - HIPAA Academy's Seal of Trust

The ComplianceALL(TM) Program provides a 360-degree end-to-end compliance service spectrum that is designed to meet specific requirements. With a complete program, the end product will be a comprehensively documented computer network system, standardized and configured with a full Backup and Disaster Recovery System (BDRS), maintained through a Remote Monitoring and Support Site. The solution eliminates the required need for extensive training in IT, time for planning, time for documentation, time for solution research, time for identifying and applying controls to minimize common vulnerabilities and risk to EPHI, time for evaluations, and payroll for personnel required to maintain this program.

Importantly, it makes available a fully documented and comprehensive presentation for a surveyor to research or for an employee or staff member to reference in case of an incident.

The ComplianceALL(TM) Program is a turn-key solution with a mission to help protect EPHI for the small business sector. ComplianceALL(TM) is built on the idea that small practitioner "Covered Entities" should have a chance to comply without high costs, and should have available resources at all times for their protection under the law and the protection of their sensitive patient information.

About ecfirst and HIPAA Academy

With over 1400 clients since 1999 and recognized as an Inc. 500 firm -- America's fastest growing Top 500 privately held business in 2004, ecfirst has enabled hundreds of organizations all across the United States and abroad
'/>"/>

SOURCE DumaTek
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Affordability Crisis in Managed Care Explored at Conference of Health Plan Executives
2. Anthem Blue Cross Statement on Settlement Discussions with the California Department of Managed Health Care
3. Rising Medical Solutions, Inc. Expands Its California Managed Care Services to Include Utilization Review Program
4. HighPoint Solutions Signs Deal to Implement Model N Managed Care and Government Pricing System for Specialty Pharmaceutical Company
5. Texas Moves Foster Children Into Managed Care Plan
6. Qforma Unveils Managed Care Optimization Solution for Pharma Marketing Executives
7. ACMs Managed Medicaid Assist Program to Enhance Care Delivered to Carolina Crescent Health Plan Members
8. CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization
9. Dollar Thrifty Automotive Group Expands Mobile Managed Services Contract with InfoLogix
10. Darwin Introduces New Managed Care Corporate Liability Insurance
11. Valley Baptist Health System Leveraging TITAN Technology Partners Hosting and Managed Services
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3NASA Research Reveals Major Insight Into Evolution of Life on Earth 4870 1NASA Research Reveals Major Insight Into Evolution of Life on Earth 4870 2The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 1The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 2The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 3The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 4Patch Shots May Someday Replace Injections 54893 1Patch Shots May Someday Replace Injections 54893 2
Other Medicine Technology:New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 2New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 4New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 5New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 6SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 2SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 3SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 4SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 5SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 6SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 7